NCT05414786View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

eOD-GT8 60mer mRNA Vaccine (100µg)

"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"

Trial Locations (2)

250

Center for Family Health Research, Kigali

1332

Aurum Tembisa Clinical Research Centre, Johannesburg

Sponsors
All Listed Sponsors
collaborator

AURUM Tembisa Clinical Research

UNKNOWN

collaborator

Center for Family Health Research

UNKNOWN

collaborator

ModernaTX, Inc.

INDUSTRY

lead

International AIDS Vaccine Initiative

NETWORK